http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Biyun Wang (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
Wang Tiyuan,Zhang Shouyang,Ren Biyun,Li Kun,Li Wei,Li Hejun 한국물리학회 2020 Current Applied Physics Vol.20 No.10
The present study explored the effect of medium texture (MT) content on flexural properties and thermal expansion coefficients (CTES) of carbon/carbon (C/C) composites with multilayered pyrolytic carbon. The specimen with 39% MT exhibited maximum flexural strength of 221.55 MPa, increasing by 52% compared with pure high texture. While the flexural strength decreased when the MT content exceeded 39%. The excellent strength can be attributed to crack deflection between multilayered texture and the strong interface bonding between fibers and matrix. Moreover, the four specimens expressed a similar trend of CTES in the direction of XY and Z. In the direction of XY, the specimen with 39% MT had the lowest CTES from 800 ◦C to 2100 ◦C. Therefore, the C/C composites with 39% MT have the best mechanical and thermal expansion properties, which means that the properties of C/C composites can be optimized by controlling the texture.
-
Hosgood III, H. Dean,Wang, Wen-Chang,Hong, Yun-Chul,Wang, Jiu-Cun,Chen, Kexin,Chang, I-Shou,Chen, Chien-Jen,Lu, Daru,Yin, Zhihua,Wu, Chen,Zheng, Wei,Qian, Biyun,Park, Jae Yong,Kim, Yeul Hong,Chatterje Springer-Verlag 2012 HUMAN GENETICS Vol.131 No.7
<P>A recent genome-wide association study (GWAS) of subjects from Japan and South Korea reported a novel association between the TP63 locus on chromosome 3q28 and risk of lung adenocarcinoma (p = 7.3 10(-12)); however, this association did not achieve genome-wide significance (p 10(-7)) among never-smoking males or females. To determine if this association with lung cancer risk is independent of tobacco use, we genotyped the TP63 SNPs reported by the previous GWAS (rs10937405 and rs4488809) in 3,467 never-smoking female lung cancer cases and 3,787 never-smoking female controls from 10 studies conducted in Taiwan, Mainland China, South Korea, and Singapore. Genetic variation in rs10937405 was associated with risk of lung adenocarcinoma [n = 2,529 cases; p = 7.1 10(-8); allelic risk = 0.80, 95% confidence interval (CI) = 0.74-0.87]. There was also evidence of association with squamous cell carcinoma of the lung (n = 302 cases; p = 0.037; allelic risk = 0.82, 95% CI = 0.67-0.99). Our findings provide strong evidence that genetic variation in TP63 is associated with the risk of lung adenocarcinoma among Asian females in the absence of tobacco smoking.</P>
-
Ying Lin,Mingxi Lin,Jian Zhang,Biyun Wang,Zhonghua Tao,Yiqun Du,Sheng Zhang,Jun Cao,Leiping Wang,Xichun Hu 대한암학회 2020 Cancer Research and Treatment Vol.52 No.4
Purpose Pyrotinib is a newly-developed irreversible pan-ErbB receptor tyrosine kinase inhibitor. This study reported the first real-world data of pyrotinib-based therapy in metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC), focusing on efficacy in lapatinib-treated patients and in brain metastasis. Materials and Methods One hundred thirteen patients with metastatic HER2-positive BC treated with pyrotinib-based therapy in Fudan University Shanghai Cancer Center under non-clinical trial settings from September 1, 2018 to March 1, 2019 were included. Results Over half patients have received more than two lines of systematic therapy and exposed to two or more kinds of anti-HER2 agents. Most patients received a combined therapy, commonly of pyrotinib plus capecitabine, or vinorelbine or trastuzumab. Median progression-free survival (PFS) was 6.3 months (range, 5.54 to 7.06 months) and objective response rate (ORR) was 29.5%, with two patients (1.9%) achieving complete response. Lapatinib-naïve patients had significantly longer PFS than lapatinib-treated patients (9.0 months vs. 5.4 months, p=0.001). ORR for lapatinib-treated patients was 23.2%. Thirty-one of 113 patients have brain metastasis. Median PFS was 6.7 months and intracranial ORR was 28%. For patients without concurrent radiotherapy and/or brain surgery, the ORR was very low (6.3%). But for patients receiving concurrent radiotherapy and/or brain surgery, the ORR was 66.7%, and three patients achieved complete response. Most common adverse event was diarrhea. Conclusion Pyrotinib-based therapy demonstrated promising effects in metastatic HER2-positive BC and showed activity in lapatinib-treated patients. For patients with brain metastasis, pyrotinib-based regimen without radiotherapy showed limited efficacy, but when combined with radiotherapy it showed promising intracranial control.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
